Pembrolizumab plus pemetrexed and platinum chemotherapy is currently the category 1, preferred regimen in US National Comprehensive Cancer Network guidelines for patients with advanced or metastatic nonsquamous NSCLC, no targetable genomic aberrations, and good performance status (Eastern Cooperative Oncology Group performance status [ECOG PS] of 0 or 1), independent of tumor PD-L1 expression (7). The gene discussed is CD274; the disease is neoplasm.